We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Targeted Therapy in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia or Acute Myelogenous Leukemia

This study is currently recruiting participants.
Verified September 2017 by Stephen Spurgeon, OHSU Knight Cancer Institute
Sponsor:
ClinicalTrials.gov Identifier:
NCT01620216
First Posted: June 15, 2012
Last Update Posted: September 22, 2017
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
Collaborator:
National Cancer Institute (NCI)
Information provided by (Responsible Party):
Stephen Spurgeon, OHSU Knight Cancer Institute
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study is currently recruiting participants.
  Estimated Study Completion Date: March 30, 2019
  Estimated Primary Completion Date: March 30, 2019 (Final data collection date for primary outcome measure)